Izou Partners Research
Investment Thesis
Izou Partners is a Chicago venture firm that invests in companies focused on the future of work, human health, and longevity. Its website says it looks for ambitious founders building high-growth businesses with clear vision, strong execution, and a deep understanding of the problem they are solving. It says it does not chase hype and backs resilience, execution, and the right people tackling the right problem at the right time. The firm wants to be among a company's earliest believers, whether the founder is redefining a category or inventing a new one.
Stage Focus
Its LinkedIn page says it invests in companies raising Seed, Seed+, and Series A rounds, when the path forward is clear enough to believe in but flexible enough to shape. The firm describes itself as investing in growth-stage companies at Seed and Series A.
Check Size
Izou does not publish a check size or fund size. Third-party data shows round sizes of $3M (seed), $5M (seed) and $10M (Series A) in rounds it joined, but those are total round sizes, not Izou's own checks. Check size is left unset.
Lead Tendency
The Venture Codex records three Izou rounds in 2026: one led (CareLumi seed, $3M) and two participated (Axo Longevity $5M seed, Chata.ai $10M Series A). That is a mixed pattern, so lead tendency is recorded as both. The sample is small.
Recent Activity
- CareLumi: led a $3M seed (Nov 2026 per The Venture Codex).
- Axo Longevity: participated in a $5M seed (Sep 2026).
- Chata.ai: participated in a $10M Series A (Jan 2026).
- A vehicle named Izou Partners Two LLC reported raising $3.0M in a Dec 2025 filing aggregated by Global Dealflow, which suggests a second investment vehicle is active. This is not confirmed by the firm itself.
Portfolio Highlights
The portfolio page lists ten current companies, grouped by the firm into Health & Longevity and Future of Work:
- Athlete Blood Test: performance-health biomarker platform for athletes and teams.
- Aurelion Bioscience: biotech running Phase 1 studies for heart and brain health.
- Autopoietic: OODAI, an AI-native personal intelligence platform.
- Axo Longevity: preventive-health membership built on 100+ biomarkers.
- CareLumi: AI infrastructure for provider credentialing and compliance.
- Chata: deterministic-AI enterprise analytics.
- Evergreen: better-for-you frozen breakfast brand.
- Kazadi Enterprises: climate-tech for industrial air drying and cold chain.
- Ocient: petabyte-scale data infrastructure.
- Thingz: agentic digital twins for industrial operations.
No exits are listed on the site.
Team
- Jeremie Bacon, Managing Partner: also Operating Partner at Muditā Venture Partners and a strategy instructor at the University of Chicago Booth School of Business. Over about 25 years he founded, scaled and sold companies in CRM, investor relations, portfolio management, marketing automation, high-frequency trading, customer success and document management. He co-founded The Forge, an outdoor recreation platform, and oversees the non-profit Wilder World Trust.
LinkedIn shows one employee on the page and a 2-10 person company. Only Bacon is named publicly.
Decision Process
Not disclosed. With one named partner, decisions look closely held, but that is an inference, so no decision process or timeline is recorded.
Founder Preferences
The firm says its capital comes with operating experience, strategic insight and real talk. The partners say they have built, scaled and sold companies worth billions, so they position as steady operators who help with strategy, team building and go-to-market.
Geographic Focus
Based at 20 N Wacker Drive, Chicago. The portfolio includes Chicago companies (CareLumi, Chata) and other US companies. The Venture Codex lists Canada, the UK and the US as deal geographies. No stated geographic restriction on the site.
Gaps
No fund size, AUM, check size, or additional partners could be found. Athlete Blood Test appears on the portfolio page only under an abbreviated logo filename, so it is described here but is not in the structured portfolio list.